H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Allakos (NASDAQ:ALLK) Inc on Monday, setting a price target of $230, which is approximately 179.16% above the present share price of $82.39.
Trucchio expects Allakos Inc to post earnings per share (EPS) of -$1.07 for the third quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Allakos, with an average price target of $167.33.
The analysts price targets range from a high of $230 to a low of $122.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$57.2 million. The company's market cap is $4.45 billion.
According to TipRanks.com, H.C. Wainwright analyst Patrick Trucchio is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.7% and a 30.89% success rate.
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood (NYSE:RWT), CA.